The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical and Vaccine Immunology

• Publication date

  2012-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/CVI.00393-12PMID 22855389PMCID PMC3485889
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The complement system. Overview.

  2014cited by this paper
• Complement Receptor 1 Expression on Mouse Erythrocytes Mediates Clearance of Streptococcus pneumoniae by Immune Adherence

  2010cited by this paper
• Immunization of Mice with Single PspA Fragments Induces Antibodies Capable of Mediating Complement Deposition on Different Pneumococcal Strains and Cross-Protection

  2010cited by this paper
• Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

  2008cited by this paper
• PspA and PspC Minimize Immune Adherence and Transfer of Pneumococci from Erythrocytes to Macrophages through Their Effects on Complement Activation

  2007cited by this paper
• CD44-mediated phagocytosis induces inside-out activation of complement receptor-3 in murine macrophages.

  2007influential reference
• Pneumolysin, PspA, and PspC Contribute to Pneumococcal Evasion of Early Innate Immune Responses during Bacteremia in Mice

  2007cited by this paper
• Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries.

  2006cited by this paper
• Roles of the Alternative Complement Pathway and C1q during Innate Immunity to Streptococcus pyogenes

  2006cited by this paper
• Pneumonia - The forgotten killer of children

  2006cited by this paper
• Antibodies to Complement Receptor 3 Treat Established Inflammation in Murine Models of Colitis and a Novel Model of Psoriasiform Dermatitis

  2006influential reference
• Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface

  2004cited by this paper
• [Pneumococcal polysaccharide vaccine].

  2004cited by this paper
• Pneumococcal polysaccharide vaccine.

  2004cited by this paper
• Lipoprotein PsaA in Virulence of Streptococcus pneumoniae: Surface Accessibility and Role in Protection from Superoxide

  2004cited by this paper
• The Virulence Function of Streptococcus pneumoniae Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection1

  2004cited by this paper
• Genetic Alteration of Capsule Type but Not PspA Type Affects Accessibility of Surface-Bound Complement and Surface Antigens of Streptococcus pneumoniae

  2003cited by this paper
• Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection

  2003cited by this paper
• Toll-Like Receptor 2 Participates in Mediation of Immune Response in Experimental Pneumococcal Meningitis1

  2003cited by this paper
• Activation of CR3‐mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3‐kinase, and protein kinase C ζ

  2003cited by this paper
• Both Family 1 and Family 2 PspA Proteins Can Inhibit Complement Deposition and Confer Virulence to a Capsular Serotype 3 Strain of Streptococcus pneumoniae

  2003cited by this paper
• Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli.

  2003cited by this paper
• Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.

  2003cited by this paper
• Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium Vaccine

  2002cited by this paper
• The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice

  2002cited by this paper
• Role of Pneumococcal Surface Protein C in Nasopharyngeal Carriage and Pneumonia and Its Ability To Elicit Protection against Carriage of Streptococcus pneumoniae

  2002cited by this paper
• Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3.

  2002cited by this paper
• Pattern recognition receptors: doubling up for the innate immune response.

  2002cited by this paper
• Phagocytosis of microbes: complexity in action.

  2002cited by this paper
• Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity against Streptococcus pneumoniae Infection

  2001cited by this paper
• Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniae

  2001cited by this paper
• Additive Attenuation of Virulence ofStreptococcus pneumoniae by Mutation of the Genes Encoding Pneumolysin and Other Putative Pneumococcal Virulence Proteins

  2000cited by this paper
• Diversity of PspA: Mosaic Genes and Evidence for Past Recombination in Streptococcus pneumoniae

  2000cited by this paper
• Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

  2000cited by this paper
• The complement system: an overview.

  2000cited by this paper
• Complement methods and protocols

  2000cited by this paper
• Role of complement in host defense against bacterial infection.

  1999cited by this paper
• Pneumococcal Surface Protein A Inhibits Complement Activation by Streptococcus pneumoniae

  1999cited by this paper
• The pspC Gene of Streptococcus pneumoniae Encodes a Polymorphic Protein, PspC, Which Elicits Cross-Reactive Antibodies to PspA and Provides Immunity to Pneumococcal Bacteremia

  1999cited by this paper
• Resistance to Both Complement Activation and Phagocytosis in Type 3 Pneumococci Is Mediated by the Binding of Complement Regulatory Protein Factor H

  1999cited by this paper
• C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity.

  1999cited by this paper
• Comparison of the PspA Sequence from Streptococcus pneumoniae EF5668 to the Previously Identified PspA Sequence from Strain Rx1 and Ability of PspA from EF5668 To Elicit Protection against Pneumococci of Different Capsular Types

  1998cited by this paper
• Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.

  1997cited by this paper
• Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA

  1994cited by this paper
• Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles.

  1993cited by this paper
• Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene

  1992cited by this paper
• Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae

  1990cited by this paper
• Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens

  1989cited by this paper
• Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion.

  1989cited by this paper
• Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA)

  1987cited by this paper
• Genetic control of the susceptibility to pneumococcal infection.

  1986cited by this paper
• Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae

  1984cited by this paper
• The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream.

  1983cited by this paper
• Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor

  1982influential reference
• Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway.

  1978cited by this paper
• Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).

  1970cited by this paper
• STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES

  1944cited by this paper

• Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice

  2025cites this paper
• Advances in the Mechanism of Streptococcus Pneumoniae Surface Proteins Evading the Immune Response Mediated by the Complement System

  2025cites this paper
• Streptococcus pneumoniae secretion chaperones PrsA, SlrA, and HtrA are required for competence, antibiotic resistance, colonization, and invasive disease

  2024cites this paper
• Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections

  2024cites this paper
• Pneumococcal surface protein A (PspA) prevents killing of Streptococcus pneumoniae by indolicidin

  2024cites this paper
• A clade of Streptococcus pneumoniae clonal complex 320 with increased tolerance to β-lactam antibiotics in a Chinese metropolitan city.

  2024cites this paper
• Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate

  2023cites this paper
• Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein A in combination with pneumococcal histidine triad protein D

  2023cites this paper
• Establishment of a modified opsonophagocytic killing assay for anti-pneumococcal surface protein A antibody.

  2023cites this paper
• Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies

  2022cites this paper
• Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals

  2021cites this paper
• A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.

  2021cites this paper
• Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates

  2021cites this paper
• State-of-the-art in the pneumococcal field: Proceedings of the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11)

  2020cites this paper
• Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A

  2020cites this paper
• PspA facilitates evasion of pneumococci from bactericidal activity of neutrophil extracellular traps (NETs).

  2019cites this paper
• Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.

  2019cites this paper
• Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens

  2019cites this paper
• The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA

  2019cites this paper
• Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections

  2019cites this paper
• Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.

  2018cites this paper
• The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine.

  2018cites this paper
• A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains

  2018cites this paper
• PSAA encapsulated mucoadhesive polycaprolactone microparticles as potential intranasal vaccine delivery system against pneumococcal infections / by Yamini Gorantla

  2017cites this paper
• Towards Identifying Protective B-Cell Epitopes: The PspA Story

  2017cites this paper
• Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity

  2017cites this paper
• IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine.

  2017cites this paper
• Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism

  2017cites this paper
• Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.

  2017cites this paper
• Infectious Diseases of the Brain

  2017cites this paper
• Investigation in to the functional role of Rgg Quorum Sensing Systems in Streptococcus pneumoniae

  2017cites this paper
• Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies

  2017cites this paper
• A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood

  2017cites this paper
• Utilization of Cholera Toxin B as an Adjuvant for the Subunit PspA Vaccine, Provides Effective Protection against Streptococcus pneumoniae Challenge

  2016influential citation
• The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin.

  2016cites this paper
• Rationale and prospects for novel pneumococcal vaccines

  2016cites this paper
• Desenvolvimento de vacinas proteicas contra Streptococcus pneumoniae: caracterização dos componentes adjuvantes da vacina celular pertussis e analise de novas combinações vacinais

  2015cites this paper
• Studies on transcriptional regulation of pyruvate formate lyase in Streptococcus pneumoniae

  2015cites this paper
• Pneumococcal Pili and Adhesins

  2015cites this paper
• Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae

  2015cites this paper
• Combined effects of lactoferrin and lysozyme on Streptococcus pneumoniae killing.

  2015cites this paper
• Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

  2015cites this paper
• Current status and perspectives on protein-based pneumococcal vaccines

  2015influential citation
• A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A

  2015cites this paper
• The role of autophagy in infection with S. pneumoniae

  2014cites this paper
• between in vitro complement deposition and passive mouse protection

  2014cites this paper
• Correlation between In Vitro Complement Deposition and Passive Mouse Protection of Anti-Pneumococcal Surface Protein A Monoclonal Antibodies

  2014cites this paper
• Review: current and new generation pneumococcal vaccines.

  2014cites this paper
• Silver polyvinyl pyrrolidone nanoparticles exhibit a capsular polysaccharide influenced bactericidal effect against Streptococcus pneumoniae

  2014cites this paper
• Pathogens Penetrating the Central Nervous System: Infection Pathways and the Cellular and Molecular Mechanisms of Invasion

  2014cites this paper
• Understanding the nasopharyngeal carriage dynamics of Streptococcus pneumoniae and other microbiota in Malawian children and adults

  2014cites this paper
• A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

  2013cites this paper
• Vaccination for the control of childhood bacterial pneumonia — Haemophilus influenzae type b and pneumococcal vaccines

  2013cites this paper
• PspA Family Distribution, Antimicrobial Resistance and Serotype of Streptococcus pneumoniae Isolated from Upper Respiratory Tract Infections in Japan

  2013cites this paper
• Current concepts in host–microbe interaction leading to pneumococcal pneumonia

  2013cites this paper
• Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

  2013cites this paper
• Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

  2013cites this paper
• Modified Opsonization, Phagocytosis, and Killing Assays To Measure Potentially Protective Antibodies against Pneumococcal Surface Protein A

  2013influential citation
• PhosphocholineC-Reactive Protein to Cell-Surface Surface by Competing with the Binding of Pneumococcal Complement Deposition on the Pneumococcal Surface Protein A Inhibits

  2012cites this paper
• Pneumococcal Surface Protein A Inhibits Complement Deposition on the Pneumococcal Surface by Competing with the Binding of C-Reactive Protein to Cell-Surface Phosphocholine

  2012cites this paper